Tumor Necrosis Factor Blockers in Rheumatoid Arthritis

Publisher Website
Google Scholar
Abstract
For patients with rheumatoid arthritis, a new era in treatment has begun. This optimistic view, shared widely by rheumatologists, reflects the introduction in the past two years of novel agents to treat this painful and debilitating condition. These agents, including the tumor necrosis factor (TNF) blockers, are the fruits of biotechnology and bring improvements in efficacy and safety. Furthermore, children will be among the candidates for these new treatments, since as shown by the results reported by Lovell et al. in this issue of the Journal, 1 children with juvenile rheumatoid arthritis, like adults, have an impressive response to TNF blockade. . . .